The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Soft Tissue Sarcoma Targeted Drugs Market Research Report 2025
Synopsis
The global Soft Tissue Sarcoma Targeted Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Soft Tissue Sarcoma Targeted Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Soft Tissue Sarcoma Targeted Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Soft Tissue Sarcoma Targeted Drugs in Hospitals is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Soft Tissue Sarcoma Targeted Drugs include Roche, Pfizer, Johnson & Johnson, GSK Plc, Teva Pharmaceuticals, Celgene, Bristol Myers Squibb, BeiGene and Shenzhen Chipscreen, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Soft Tissue Sarcoma Targeted Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Soft Tissue Sarcoma Targeted Drugs.
Report Scope
The Soft Tissue Sarcoma Targeted Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Soft Tissue Sarcoma Targeted Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Soft Tissue Sarcoma Targeted Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Pfizer
Johnson & Johnson
GSK Plc
Teva Pharmaceuticals
Celgene
Bristol Myers Squibb
BeiGene
Shenzhen Chipscreen
Monopar Therapeutics
Akeso Biopharma
Segment by Type
Local Sarcoma
Metastatic Sarcoma
Other Sarcoma
Segment by Application
Hospitals
Oncology Centers
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Soft Tissue Sarcoma Targeted Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global Soft Tissue Sarcoma Targeted Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Soft Tissue Sarcoma Targeted Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Soft Tissue Sarcoma Targeted Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Soft Tissue Sarcoma Targeted Drugs in Hospitals is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Soft Tissue Sarcoma Targeted Drugs include Roche, Pfizer, Johnson & Johnson, GSK Plc, Teva Pharmaceuticals, Celgene, Bristol Myers Squibb, BeiGene and Shenzhen Chipscreen, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Soft Tissue Sarcoma Targeted Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Soft Tissue Sarcoma Targeted Drugs.
Report Scope
The Soft Tissue Sarcoma Targeted Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Soft Tissue Sarcoma Targeted Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Soft Tissue Sarcoma Targeted Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Pfizer
Johnson & Johnson
GSK Plc
Teva Pharmaceuticals
Celgene
Bristol Myers Squibb
BeiGene
Shenzhen Chipscreen
Monopar Therapeutics
Akeso Biopharma
Segment by Type
Local Sarcoma
Metastatic Sarcoma
Other Sarcoma
Segment by Application
Hospitals
Oncology Centers
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Soft Tissue Sarcoma Targeted Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Soft Tissue Sarcoma Targeted Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Local Sarcoma
1.2.3 Metastatic Sarcoma
1.2.4 Other Sarcoma
1.3 Market by Application
1.3.1 Global Soft Tissue Sarcoma Targeted Drugs Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Oncology Centers
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Soft Tissue Sarcoma Targeted Drugs Market Perspective (2019-2030)
2.2 Soft Tissue Sarcoma Targeted Drugs Growth Trends by Region
2.2.1 Global Soft Tissue Sarcoma Targeted Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Soft Tissue Sarcoma Targeted Drugs Historic Market Size by Region (2019-2024)
2.2.3 Soft Tissue Sarcoma Targeted Drugs Forecasted Market Size by Region (2025-2030)
2.3 Soft Tissue Sarcoma Targeted Drugs Market Dynamics
2.3.1 Soft Tissue Sarcoma Targeted Drugs Industry Trends
2.3.2 Soft Tissue Sarcoma Targeted Drugs Market Drivers
2.3.3 Soft Tissue Sarcoma Targeted Drugs Market Challenges
2.3.4 Soft Tissue Sarcoma Targeted Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Soft Tissue Sarcoma Targeted Drugs Players by Revenue
3.1.1 Global Top Soft Tissue Sarcoma Targeted Drugs Players by Revenue (2019-2024)
3.1.2 Global Soft Tissue Sarcoma Targeted Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Soft Tissue Sarcoma Targeted Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Soft Tissue Sarcoma Targeted Drugs Revenue
3.4 Global Soft Tissue Sarcoma Targeted Drugs Market Concentration Ratio
3.4.1 Global Soft Tissue Sarcoma Targeted Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Soft Tissue Sarcoma Targeted Drugs Revenue in 2023
3.5 Soft Tissue Sarcoma Targeted Drugs Key Players Head office and Area Served
3.6 Key Players Soft Tissue Sarcoma Targeted Drugs Product Solution and Service
3.7 Date of Enter into Soft Tissue Sarcoma Targeted Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Soft Tissue Sarcoma Targeted Drugs Breakdown Data by Type
4.1 Global Soft Tissue Sarcoma Targeted Drugs Historic Market Size by Type (2019-2024)
4.2 Global Soft Tissue Sarcoma Targeted Drugs Forecasted Market Size by Type (2025-2030)
5 Soft Tissue Sarcoma Targeted Drugs Breakdown Data by Application
5.1 Global Soft Tissue Sarcoma Targeted Drugs Historic Market Size by Application (2019-2024)
5.2 Global Soft Tissue Sarcoma Targeted Drugs Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Soft Tissue Sarcoma Targeted Drugs Market Size (2019-2030)
6.2 North America Soft Tissue Sarcoma Targeted Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Soft Tissue Sarcoma Targeted Drugs Market Size by Country (2019-2024)
6.4 North America Soft Tissue Sarcoma Targeted Drugs Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Soft Tissue Sarcoma Targeted Drugs Market Size (2019-2030)
7.2 Europe Soft Tissue Sarcoma Targeted Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Soft Tissue Sarcoma Targeted Drugs Market Size by Country (2019-2024)
7.4 Europe Soft Tissue Sarcoma Targeted Drugs Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Soft Tissue Sarcoma Targeted Drugs Market Size (2019-2030)
8.2 Asia-Pacific Soft Tissue Sarcoma Targeted Drugs Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Soft Tissue Sarcoma Targeted Drugs Market Size by Region (2019-2024)
8.4 Asia-Pacific Soft Tissue Sarcoma Targeted Drugs Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Soft Tissue Sarcoma Targeted Drugs Market Size (2019-2030)
9.2 Latin America Soft Tissue Sarcoma Targeted Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Soft Tissue Sarcoma Targeted Drugs Market Size by Country (2019-2024)
9.4 Latin America Soft Tissue Sarcoma Targeted Drugs Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Soft Tissue Sarcoma Targeted Drugs Market Size (2019-2030)
10.2 Middle East & Africa Soft Tissue Sarcoma Targeted Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Soft Tissue Sarcoma Targeted Drugs Market Size by Country (2019-2024)
10.4 Middle East & Africa Soft Tissue Sarcoma Targeted Drugs Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Detail
11.1.2 Roche Business Overview
11.1.3 Roche Soft Tissue Sarcoma Targeted Drugs Introduction
11.1.4 Roche Revenue in Soft Tissue Sarcoma Targeted Drugs Business (2019-2024)
11.1.5 Roche Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Detail
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Soft Tissue Sarcoma Targeted Drugs Introduction
11.2.4 Pfizer Revenue in Soft Tissue Sarcoma Targeted Drugs Business (2019-2024)
11.2.5 Pfizer Recent Development
11.3 Johnson & Johnson
11.3.1 Johnson & Johnson Company Detail
11.3.2 Johnson & Johnson Business Overview
11.3.3 Johnson & Johnson Soft Tissue Sarcoma Targeted Drugs Introduction
11.3.4 Johnson & Johnson Revenue in Soft Tissue Sarcoma Targeted Drugs Business (2019-2024)
11.3.5 Johnson & Johnson Recent Development
11.4 GSK Plc
11.4.1 GSK Plc Company Detail
11.4.2 GSK Plc Business Overview
11.4.3 GSK Plc Soft Tissue Sarcoma Targeted Drugs Introduction
11.4.4 GSK Plc Revenue in Soft Tissue Sarcoma Targeted Drugs Business (2019-2024)
11.4.5 GSK Plc Recent Development
11.5 Teva Pharmaceuticals
11.5.1 Teva Pharmaceuticals Company Detail
11.5.2 Teva Pharmaceuticals Business Overview
11.5.3 Teva Pharmaceuticals Soft Tissue Sarcoma Targeted Drugs Introduction
11.5.4 Teva Pharmaceuticals Revenue in Soft Tissue Sarcoma Targeted Drugs Business (2019-2024)
11.5.5 Teva Pharmaceuticals Recent Development
11.6 Celgene
11.6.1 Celgene Company Detail
11.6.2 Celgene Business Overview
11.6.3 Celgene Soft Tissue Sarcoma Targeted Drugs Introduction
11.6.4 Celgene Revenue in Soft Tissue Sarcoma Targeted Drugs Business (2019-2024)
11.6.5 Celgene Recent Development
11.7 Bristol Myers Squibb
11.7.1 Bristol Myers Squibb Company Detail
11.7.2 Bristol Myers Squibb Business Overview
11.7.3 Bristol Myers Squibb Soft Tissue Sarcoma Targeted Drugs Introduction
11.7.4 Bristol Myers Squibb Revenue in Soft Tissue Sarcoma Targeted Drugs Business (2019-2024)
11.7.5 Bristol Myers Squibb Recent Development
11.8 BeiGene
11.8.1 BeiGene Company Detail
11.8.2 BeiGene Business Overview
11.8.3 BeiGene Soft Tissue Sarcoma Targeted Drugs Introduction
11.8.4 BeiGene Revenue in Soft Tissue Sarcoma Targeted Drugs Business (2019-2024)
11.8.5 BeiGene Recent Development
11.9 Shenzhen Chipscreen
11.9.1 Shenzhen Chipscreen Company Detail
11.9.2 Shenzhen Chipscreen Business Overview
11.9.3 Shenzhen Chipscreen Soft Tissue Sarcoma Targeted Drugs Introduction
11.9.4 Shenzhen Chipscreen Revenue in Soft Tissue Sarcoma Targeted Drugs Business (2019-2024)
11.9.5 Shenzhen Chipscreen Recent Development
11.10 Monopar Therapeutics
11.10.1 Monopar Therapeutics Company Detail
11.10.2 Monopar Therapeutics Business Overview
11.10.3 Monopar Therapeutics Soft Tissue Sarcoma Targeted Drugs Introduction
11.10.4 Monopar Therapeutics Revenue in Soft Tissue Sarcoma Targeted Drugs Business (2019-2024)
11.10.5 Monopar Therapeutics Recent Development
11.11 Akeso Biopharma
11.11.1 Akeso Biopharma Company Detail
11.11.2 Akeso Biopharma Business Overview
11.11.3 Akeso Biopharma Soft Tissue Sarcoma Targeted Drugs Introduction
11.11.4 Akeso Biopharma Revenue in Soft Tissue Sarcoma Targeted Drugs Business (2019-2024)
11.11.5 Akeso Biopharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
